Mark Day
Directeur/Membre du Conseil chez Aeromics, Inc.
Profil
Mark Day is currently the Director at Aeromics, Inc. He was previously the President, Chief Executive Officer & Director at biOasis Technologies, Inc. from 2017 to 2019, the Executive Director & Head-External Research at Alexion Pharmaceuticals, Inc. from 2014 to 2016, and the Independent Director at NanoViricides, Inc. from 2019 to 2020.
He also held positions at Purdue Pharma (Canada) as the Head-CNS Virtual Discovery from 2016 to 2017, and at Abbott Laboratories, Inc. as the Head-Biochemical Bio Markets.
Dr. Day received his undergraduate and doctorate degrees from the University of Cardiff.
Postes actifs de Mark Day
| Sociétés | Poste | Début |
|---|---|---|
Aeromics, Inc.
 Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | Directeur/Membre du Conseil | 16/08/2018 |
Anciens postes connus de Mark Day
| Sociétés | Poste | Fin |
|---|---|---|
| NANOVIRICIDES, INC. | Directeur/Membre du Conseil | 29/05/2020 |
| BIOASIS TECHNOLOGIES INC. | Directeur Général | 11/03/2019 |
Purdue Pharma (Canada)
 Purdue Pharma (Canada) Pharmaceuticals: MajorHealth Technology Purdue Pharma (Canada) manufactures and markets pharmaceutical products. It products for the treatment of pain, respiratory disease, gastrointestinal disorders, and infection control. The firm include laxatives, bronchodilators, antiseptics, and analgesics. Purdue Pharma is headquartered in Pickering, Canada | Corporate Officer/Principal | 01/04/2017 |
| ALEXION PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/10/2016 |
Abbott Laboratories, Inc.
 Abbott Laboratories, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Inc., the company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL. | Corporate Officer/Principal | - |
Formation de Mark Day
| University of Cardiff | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| NANOVIRICIDES, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 4 |
|---|---|
Purdue Pharma (Canada)
Purdue Pharma (Canada) Pharmaceuticals: MajorHealth Technology Purdue Pharma (Canada) manufactures and markets pharmaceutical products. It products for the treatment of pain, respiratory disease, gastrointestinal disorders, and infection control. The firm include laxatives, bronchodilators, antiseptics, and analgesics. Purdue Pharma is headquartered in Pickering, Canada | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | Health Technology |
Abbott Laboratories, Inc.
Abbott Laboratories, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Inc., the company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL. | Health Technology |
